MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Market Cap 2011-2026 | ZOM
As of April 10, 2026 Zomedica Corp. has a market cap of $ 98 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 137 M | 245 M | 297 M | 335 M | 25.9 M | 80.6 M | 175 M | 200 K | 200 K | 68 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 335 M | 68 K | 130 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
75.4 M | $ 18.02 | -2.12 % | $ 115 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 3.11 | -0.96 % | $ 43.7 M | USA |
 |
Cronos Group
CRON
|
3.63 B | $ 2.55 | 0.79 % | $ 1.33 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
3.38 B | $ 5.39 | 0.75 % | $ 1.97 B | Canada |
 |
Harrow Health
HROW
|
1.93 B | $ 37.29 | 1.52 % | $ 1.37 B | USA |
 |
Aurora Cannabis
ACB
|
915 M | $ 3.48 | 1.46 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
142 M | $ 1.09 | 4.81 % | $ 117 M | Canada |
 |
Jupiter Wellness
JUPW
|
2.36 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
271 M | $ 4.24 | 3.67 % | $ 273 M | USA |
 |
Emergent BioSolutions
EBS
|
139 M | $ 8.45 | 0.72 % | $ 433 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
382 M | $ 1.44 | 3.6 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
415 M | $ 2.29 | -4.18 % | $ 302 M | USA |
 |
Pacira BioSciences
PCRX
|
1.18 B | $ 23.82 | 2.45 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
889 K | $ 1.38 | 1.47 % | $ 3.37 M | Canada |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
247 M | $ 7.61 | 8.56 % | $ 300 M | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 0.99 | -0.4 % | $ 49.4 M | USA |
 |
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
623 M | $ 8.1 | 1.0 % | $ 709 M | USA |
 |
Tilray
TLRY
|
1.19 B | $ 6.72 | -0.44 % | $ 4.15 B | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 2.41 | 5.24 % | $ 2.99 M | USA |
 |
Veru
VERU
|
108 M | $ 2.43 | -4.71 % | $ 328 M | USA |
 |
Viatris
VTRS
|
18.4 B | $ 13.61 | 0.29 % | $ 16.3 B | USA |
 |
cbdMD
YCBD
|
1.68 M | $ 0.65 | -6.59 % | $ 2.8 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
33.8 M | $ 0.93 | -0.98 % | $ 33.5 M | USA |
 |
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
2.75 M | $ 0.66 | 5.66 % | $ 2.83 M |  China |
 |
TherapeuticsMD
TXMD
|
23 M | $ 2.05 | - | $ 23.7 M | USA |